1-855-378-42281-855-378-4228
One of the outpatient rehabilitation options for clients in Harmon who are battling with opioid dependence and addiction is called opioid maintenance therapy. Some facilities and doctors are authorized to dispense certain medications to opioid addicted individuals, many that are opioid-based themselves and are addiction. With low enough amounts however, the individual does not experience being high and also doesn't experience intense cravings and is not in opioid withdrawal. Methadone is the first drug tried for this purpose, but there are a few more choices currently to choose from.
Methadone is an opioid and can be taken at an out-patient clinic licensed to dispense the med, which is taken on a daily basis in liquid or pill form. The cost of the med is around one hundred and fifty dolloars a month. Buprenorphine is also an opiate based drug, and is in pill form often taken one day on, one day off. But different from Methadone that can only be dispensed in structured clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The monthly cost of buprenorphine is about $300.00 monthly for the generic of the med. There is also a version of buprenorphine containing the drug naloxone, that is a med which blocks the effects of opioids. An individual taking this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and costs around $450 a month. Naltrexone is an additional med used in opioid maintenance therapy, but unlike the other medications mentioned it's an opioid blocker and is not an opiate. There is an option to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 per month.
For All Alcohol and Drug Rehabilitation Facilities In Harmon, Click Here.
